It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the US approval of three cell therapy products: Iovance ...

For biopharma companies and CDMOs, the priority will shift from isolated digital bioprocess pilots toward building an ...

Key opportunities include automated, closed and digitally monitored production; end-to-end CDMO services; viral vector capacity; scalable autologous and allogeneic platforms; regional manufacturing; ...

LONDON--(BUSINESS WIRE)--Mytos, an innovative leader in automated cell manufacturing, announced today it has closed $19M in Series A financing led by Buckley Ventures, with participation from IQ ...

Elegen and Nutcracker Therapeutics launched a pilot program to demonstrate what they label the industry’s first fully synthetic, cell-free manufacturing platform for RNA-based personalized cancer ...

Extensive testing and training process will involve approximately 10 Electrovaya staff members responsible for key ...

Commercial collaboration combines 4basebio’s synthetic DNA technology with Genezen’s viral vector development and manufacturing expertise to support gene therapy programs from early development ...